Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.

The US drugmaker Eli Lilly has bowed to demands from Donald Trump by raising the prices of its weight-loss jab for UK customers.

Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing in peer developed nations.

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its medications.

Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 million worth of stock in the aftermath of the selloff.